Melanocortin Peptide
Melanotan-1 (MT-1) is a synthetic peptide widely studied for its role in melanocortin receptor signaling, melanogenesis, and skin pigmentation modulation.
Melanocortin Peptide
Melanotan I
Melanotan-1 (MT-1) is a synthetic peptide widely studied for its role in melanocortin receptor signaling, melanogenesis, and skin pigmentation modulation.
1
$29.99
Most Popular
Best Value
Est. delivery Jul 20 - Jul 22
Free shipment protection
Secure checkout
We accept:
Free shipping
on orders over $200
Damage protection
on every order
Secure checkout
256-bit SSL
Certificate of Analysis
Tested for Identification, Purity, Mass, Endotoxins, Sterility, and Heavy Metals
LATEST
6× TESTED
99.45%
PURITY
Variant
Melanotan I 10MG
Lot #
MT1-2606-A01
Labeled
10mg
Actual
11.25mg
Tested
June 22, 2026
Heavy Metals
Within Limits
Endotoxins
Pass
Sterility
No Growth
Compound Information
Pharmaceutical Specifications
Molecular Profile
What Is Melanotan I?
TypeSynthetic peptide
CAS Number75921-69-6
Molecular FormulaC₇₈H₁₁₁N₂₁O₁₉
Molecular Weight1,646.85 g/mol
Amino Acids13
Storage Requirements
Stability Information
Lyophilized (powder)
-20°C · 24+ months
Reconstituted
2-8°C · ~30 days
Research
Sources & References
JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (AMA)
Induction of Skin Tanning by Subcutaneous Administration of a Potent Synthetic Melanotropin
View Source
NEW ENGLAND JOURNAL OF MEDICINE (NEJM/MMS)
Afamelanotide for Erythropoietic Protoporphyria
View Source
BRITISH JOURNAL OF DERMATOLOGY (WILEY/BAD)
Long-Term Observational Study of Afamelanotide in 115 Patients with Erythropoietic Protoporphyria
View Source
JAMA DERMATOLOGY (AMA/JAMA NETWORK)
Afamelanotide and Narrowband UV-B Phototherapy for the Treatment of Vitiligo: A Randomized Multicenter Trial
View Source
JAMA DERMATOLOGY (AMA/JAMA NETWORK)
Association of Afamelanotide with Improved Outcomes in Patients with Erythropoietic Protoporphyria in Clinical Practice
View Source
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (TAYLOR & FRANCIS)
Afamelanotide for Prevention of Phototoxicity in Erythropoietic Protoporphyria
View Source
LIFE (MDPI)
Afamelanotide Is Associated with Dose-Dependent Protective Effect from Liver Damage Related to Erythropoietic Protoporphyria
View Source
LIVER INTERNATIONAL (WILEY)
Erythropoietic Protoporphyrias: Pathogenesis, Diagnosis and Management
View Source
BMC NEUROLOGY (BIOMED CENTRAL/SPRINGER)
A Feasibility and Safety Study of Afamelanotide in Acute Stroke Patients: An Open Label, Proof of Concept, Phase IIa Clinical Trial
View Source
PHOTODERMATOLOGY, PHOTOIMMUNOLOGY & PHOTOMEDICINE (WILEY/ESPD)
EMA, It's Time to Reconsider! 10 Years Afamelanotide for Treating Erythropoietic Protoporphyria
View Source
